DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
FDA Maintains Record-Breaking Approval Pace Despite Organizational Upheaval, Highlighting Three Breakthrough Therapies
The FDA has approved 84 drugs in 2025 so far, marking the second-highest total for this period despite major organizational changes including 3,500 staff layoffs.
Daiichi Sankyo's New CEO Charts Course for ADC Expansion Beyond Enhertu Success
Hiroyuki Okuzawa assumed leadership of Daiichi Sankyo two months ago, inheriting a company strengthened by three major pharmaceutical licensing deals worth up to $27 billion based on ADC technology.
AbbVie's Temab-A ADC Shows 63% Response Rate in EGFR-Mutated NSCLC Phase I Trial
AbbVie's antibody drug conjugate Temab-A achieved a 63% overall response rate in patients with advanced EGFR-mutated non-small cell lung cancer in Phase I trial results presented at ASCO 2025.
HER3-DXd Demonstrates Promising Intracranial Activity in Phase II TUXEDO-3 Trial for Brain Metastases
The phase II TUXEDO-3 trial showed patritumab deruxtecan (HER3-DXd) achieved intracranial response rates of 23.8% in metastatic breast cancer and 30% in advanced non-small cell lung cancer patients with active brain metastases.
Real-World Study Shows Safe Rechallenge with Trastuzumab Deruxtecan After Grade 1 Interstitial Lung Disease
A multi-institutional study of 1,476 patients found that 75% of those with grade 1 interstitial lung disease (ILD) were successfully rechallenged with trastuzumab deruxtecan, remaining on therapy for a median of 215 days.
Merck KGaA's ADC Precemtabart Tocentecan Shows Promising Safety and Efficacy in Metastatic Colorectal Cancer Trial
Merck KGaA's antibody-drug conjugate precemtabart tocentecan demonstrated safety and tolerability in a Phase Ib trial for metastatic colorectal cancer patients.
Merck and Daiichi Sankyo Withdraw FDA Application for Lung Cancer ADC After Survival Data Disappoints
Merck and Daiichi Sankyo withdrew their FDA application for patritumab deruxtecan, an antibody-drug conjugate targeting EGFR-mutated non-small cell lung cancer, after the drug failed to demonstrate overall survival benefit.
Daiichi Sankyo and Merck Withdraw Patritumab Deruxtecan BLA After Phase 3 Trial Fails to Meet Overall Survival Endpoint
Daiichi Sankyo and Merck voluntarily withdrew their Biologics License Application for patritumab deruxtecan in EGFR-mutated NSCLC after the confirmatory HERTHENA-Lung02 Phase 3 trial failed to demonstrate statistically significant overall survival benefit.
ADC Market in NSCLC Projected to Reach $3.9 Billion by 2032, Led by AstraZeneca's Datroway
The antibody-drug conjugate (ADC) market in non-small-cell lung cancer is projected to grow at a 6.8% CAGR across seven major markets and exceed $3.9 billion by 2032.
World ADC San Diego Conference Highlights Growing Industry Focus on Antibody-Drug Conjugates
The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.